SILVER SPRING
Jakafi XR cleared for myelofibrosis, polycythemia vera, GVHD
- Sponsor
- Incyte $INCY
- Drug
- Jakafi XR · ruxolitinib
- Indication
- myelofibrosis, polycythemia vera, graft-versus-host disease
FDA approved Jakafi XR (ruxolitinib) extended-release tablets for myelofibrosis, polycythemia vera, and graft-versus-host disease in adults.
What this means
Jakafi XR is an extended-release version of ruxolitinib, a pill that blocks overactive immune signals in certain blood disorders and transplant complications. FDA approved the once-daily version for adults with myelofibrosis, polycythemia vera, or graft-versus-host disease who were already using the twice-daily form. The new formulation could make treatment easier by reducing pill burden while maintaining the same active ingredient.
Drug Watch — recent news on Jakafi XR
- Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target - Yahoo Finance
- Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial - OncLive
- Oncology HCP Perspectives Highlight Potential Benefit of Once-Daily Extended-Release Ruxolitinib - Cancer Nursing Today
- Cantor Fitzgerald reiterates Neutral on Incyte stock on Opzelura use - Investing.com
- Ruxolitinib Shows Stronger Response in Primary Than Secondary HLH, Meta-Analysis Finds - bioengineer.org